Psoriasis is a condition that has no satisfactory treatment at present.
Scientists at Strathclyde have discovered an analogue of a natural product which is an efficient cytostatic agent, decreasing the rate of cell proliferation, but it is not cytotoxic. It does not affect normal skin, unlike present steroid treatments. A small scale clinical trial has been carried out. The Strathclyde Institute for Drug Research is seeking a commercial sponsor to support and accelerate the development of these compounds, in exchange for commercial rights. For further information on this opportunity, please complete the electronic reply sheet .